Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

4,157

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

4,157 results for “Survival.”

Learn how ShareScore rates datasets ↗
geo16/100

Staphylococcus aureus modulate cellular metabolism to survive in epithelial cells

GEO Series GSE174235. Rattus norvegicus. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenMay 2021View details →
geo16/100

ESR1+ luminal epithelial cells contribute to androgen-independent prostate survival in the absence of SRD5A2

GEO Series GSE235514. Mus musculus. 3 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenJun 2023View details →
zenodo16/100

Dataset related to article "Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis."

<p>PURPOSE:</p> <p>The aim of the present study was to provide predictive factors for survival outcomes of oligometastatic prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) as a metastases-directed therapy (MDT).</p> <p>METHODS:</p> <p>In this cohort study, endpoints included overall survival (OS), progression-free survival (PFS), distant progression-free survival (DFS) and local control of treated metastases (LC). The binary classification tree approach with recursive partitioning analysis (RPA) was applied to stratify the patients into risk groups based on OS, PFS and DPFS; for each endpoint, disease-free interval (DFI) was calculated. We included patients with synchronous or metachronous metastases from prostate adenocarcinoma treated with SBRT.</p> <p>RESULTS:</p> <p>119 Metastases were treated with SBRT in 92 patients. Median follow-up was 22.2&nbsp;months. Rates of OS at 1 and 3&nbsp;years were 96.9% and 88.0%, while DPFS was 51.9% and 20.9%. Recursive partitioning analysis identified three prognostic classes for OS: Class 1: castration-sensitive patients (3&nbsp;years OS 95%); Class 2: castration-resistant patients with low-intermediate risk NCCN disease (3&nbsp;years OS 88.8%); Class 3: castration-resistant patients with high-risk NCCN disease (3&nbsp;years OS 76.9%). Regarding DPFS, RPA divided patients into two classes, according to a cutoff value of DFI of 34&nbsp;months (3&nbsp;years PFS of 28.7% vs 5.8%). Three classes were identified for DPFS: Class 1: DFI&thinsp;&lt;&thinsp;34&nbsp;months (3&nbsp;years DPFS 9.1%); Class 2: DFI&thinsp;&gt;&thinsp;34&nbsp;months and high-risk NCCN PC (3&nbsp;years DPFS 21%); Class 3: DFI&thinsp;&gt;&thinsp;34&nbsp;months and low-intermediate risk NCCN disease (3&nbsp;years DPFS 60.2%).</p> <p>CONCLUSION:</p> <p>Oligometastatic PC represents nowadays a setting of particular interest in which local ablative therapies play a decisive role. In the present study, we recognized the importance of DFI, together with NCCN class risk, to predict the risk of new metastases after SBRT in oligometastatic PC.</p>

restrictedMar 2020View details →
zenodo16/100

Dataset related to article "Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics."

<p>PURPOSE:</p> <p>To appraise the ability of a&nbsp;radiomics signature to predict clinical outcome after definitive radiochemotherapy (RCT) of stage&nbsp;III-IV head and neck cancer.</p> <p>METHODS:</p> <p>A&nbsp;cohort of 110 patients was included in a&nbsp;retrospective analysis. Radiomics texture features were extracted from the gross tumor volumes contoured on planning computed tomography (CT) images. The cohort of patients was randomly divided into a&nbsp;training (70&nbsp;patients) and a&nbsp;validation (40&nbsp;patients) cohorts. Textural features were correlated to survival and control data to build predictive models. All the significant predictors of the univariate analysis were included in a&nbsp;multivariate model. The quality of the models was appraised by means of the concordance index (CI).</p> <p>RESULTS:</p> <p>A&nbsp;signature with 3&nbsp;features was identified as predictive of overall survival (OS) with CI =&thinsp;0.88 and 0.90 for the training and validation cohorts, respectively. A&nbsp;signature with 2&nbsp;features was identified for progression-free survival (PFS; CI =&thinsp;0.72 and 0.80); 2&nbsp;features also characterized the signature for local control (LC; CI =&thinsp;0.72 and 0.82). In all cases, the stratification in high- and low-risk groups for the training and validation cohorts led to significant differences in the actuarial curves. In the validation cohort the mean OS times (in months) were 78.9 &plusmn;&thinsp;2.1 vs 67.4 &plusmn;&thinsp;6.0 in the low- and high-risk groups, respectively, the PFS was 73.1 &plusmn;&thinsp;3.7 and 50.7 &plusmn;&thinsp;7.2, while the LC was 78.7 &plusmn;&thinsp;2.1 and 63.9 &plusmn;&thinsp;6.5.</p> <p>CONCLUSION:</p> <p>CT-based radiomic signatures that correlate with survival and control after RCT were identified and allow low- and high-risk groups of patients to be identified.</p>

restrictedMar 2020View details →
zenodo16/100

Dataset related to article "Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer."

<p><strong>Aim:</strong> The association of tyrosine kinase inhibitors (TKIs) and local radiotherapy in <em>EGFR</em>-mutated non-small-cell lung cancer patients experiencing disease progression under TKIs could be a valid an option. <strong>Patients &amp; methods:</strong> We included 131 patients experiencing disease progression during first-line TKI. In group A, patients received TKI beyond progression and site(s) of progression were irradiated; in group B, patients remained on TKI alone beyond progression; and group C stopped TKI at first disease progression. <strong>Results:</strong> Median overall survival resulted longer in group A versus B and C (p&nbsp;&lt;&nbsp;0.0001). Group A had a trend toward a longer second progression-free survival (measured from the time of first progression until second progression) versus group B (p&nbsp;=&nbsp;0.06). <strong>Conclusion:</strong> TKI beyond progression in association with local ablative treatment is a valid treatment option in oligoprogressive patients.</p> <p>&nbsp;</p> <p>&nbsp;</p>

restrictedMar 2020View details →
zenodo16/100

Dataset related to article "Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy"

<p>This record contains raw data related to article &ldquo;Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy&quot;</p> <p><strong>Introduction:&nbsp;</strong>Liver and lung are common sites of metastases from colorectal cancer (CRC). Stereotactic body radiation therapy (SBRT) represents a valid treatment, with high rates of local control (LC). In this study, we applied recursive partitioning model-based analysis (RPA) to define class risks for overall survival (OS) and progression free survival (PFS) in oligometastatic CRC patients.</p> <p><strong>Materials and methods:&nbsp;</strong>In this monocentric analysis, we included patients with lung or liver metastases. Patients were candidate to SBRT if a maximum of 5 metastases. End points of the present analysis were LC, PFS, and OS. The binary classification tree approach with RPA was applied to stratify the patients into risk groups based on OS and PFS.</p> <p><strong>Results:&nbsp;</strong>218 patients were treated with SBRT on 371 metastases. Majority of patients (56%) was treated on single lesion, followed by 2 (26.1%) and 3 lesions (14.7%). Median follow-up was 22.7 months. Rates of LC were 84.2% at 1 year and 73.8% at 3 years. Rates of PFS at 1 and 3 years were 42.2% and 14.9%, respectively. RPA identified 3 classes for PFS, according to age and number of metastases with 3-year PFS of 30.6%, 13.5% and 8.4%. Overall survival was 87.2% at 1 year, 51.9% at 3 years, and 36.8% at 5 years. RPA identified 3 nodes. Class 1 included patients with liver metastases (3-year OS 35.2%). Class 2 included patients with lung metastases and DFI &le; 48 months (3-year OS 65%). Class 3 included patients with lung metastases and DFI &gt; 48 months (3-year OS 73.5%).</p> <p><strong>Conclusions:&nbsp;</strong>Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT.</p>

restrictedDec 2020View details →
zenodo16/100

DATASET RELATED TO ARTICLE "Resection of primary central nervous system lymphoma: impact of patient selection on overall survival"

<p>Patient characteristics, comorbidities, pre-operatives symptoms, lesion features, post-operatives symptoms, adjuvant therapies, histology, PFS, OS</p> <p>&nbsp;</p>

restrictedJan 2022View details →
zenodo16/100

Dataset related to article "Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients "

<p>This record contains raw data related to article &ldquo;Early age of onset is an independent predictor for worse disease-free survival in sporadic rectal cancer patients. A comparative analysis of 980 consecutive patients&quot;</p> <p><strong>Background: </strong> while interest on early-onset colorectal cancer (age &le;49) is on the rise, studies on early-onset rectal cancer (EORC) are limited. The aim of this study was to compare predictors for disease progression/recurrence between sporadic EORC and late-onset RC patients (LORC).</p> <p><strong>Methods: </strong> 163 EORC and 830 LORC operated between January 1st<sup>,</sup> 2010 and April 30th<sup>,</sup> 2021 at a tertiary center were included. Demographics, tumor characteristics, microsatellite status, gene mutations (KRAS, BRAF, NRAS, PI3Kca) and oncologic outcomes were compared. A Cox proportional hazards regression analysis was performed to ascertain the effect of variables on recurrence/progression and death. Recurrence/Progression free survival (R/PFS) and cancer specific survival (CSS) were analyzed by the Kaplan-Meier estimator.</p> <p><strong>Results: </strong> Mean age of EORC was 42.16, (46% aged 45-49). A majority of EORC patients had a family history for CRC (p = 0.01) and underwent total neoadjuvant treatment (p = 0.01). EORC patients showed a higher rate of low-grade tumor differentiation (p &lt; 0.0001), stage III-IV (p = 0.001), microsatellite instability (p = 0.02), locoregional nodal (p = 0.001) and distant metastases (p &lt; 0.0001). Accordingly, more EORC patients underwent adjuvant treatment (p &lt; 0.0001). Mutations were mostly reported among LORC cases (p = 0.04), whereas EORC patients showed a worse R/PFS (p = 0.02), even at stage I (p = 0.04). CSS did not differ (p = 0.11) across groups. Multivariate analysis indicated age of onset (p = 0.04) was an independent predictor for progression/recurrence.</p> <p><strong>Conclusions: </strong> Age of onset was shown to be an independent unfavorable predictor. Delayed diagnosis could explain this effect in the more advanced stages, while the worse outcomes in stage I may suggest a more aggressive disease behavior.</p> <p>&nbsp;</p>

restrictedJan 2022View details →
zenodo16/100

Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival"

<p>Dataset related to article &quot;Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival &quot;</p> <p>&nbsp;</p> <p>Abstract</p> <p><strong>Background:&nbsp;</strong>It is unclear whether invasive intraductal papillary mucinous neoplasm (IPMN) has different clinical and prognostic characteristics, beyond histological factors, when compared to pancreatic ductal adenocarcinoma (PDAC).</p> <p><strong>Aims:&nbsp;</strong>compare prognostic features of resected PDAC and invasive IPMN METHODS: A retrospective study of patients resected for PDAC or invasive IPMN realized at Humanitas Cancer Center&#39;s Pancreatic Surgery Unit, Milan, Italy, between 2010 and 2016. Data recorded included patient demographics, onset symptoms, preoperative health status, tumor features, histology and surgical characteristics. Overall survival was estimated using Kaplan-Meier and prognostic factors for survival were assessed by multivariate Cox regression.</p> <p><strong>Results:&nbsp;</strong>A total of 332 patients were included (PDAC, n = 289; invasive IPMN, n = 43). Patients with invasive IPMN had better overall survival than PDAC patients (median: 76.6 versus 25.6 months; 5-year OS rate: 65.4% vs. 14.2%; p &lt; 0.001). PDAC histology was associated with a significantly higher risk of death than IPMN (hazard ratio 1.815, 95% CI: 1.02, 3.24; p = 0.044). Survival was also worse with PDAC in early-stage disease (IA-IB-IIA, N0). In multivariate analysis, independent predictors of worse survival included perineural invasion, preoperative ASA physical status &ge;3 and pain at diagnosis.</p> <p><strong>Conclusions:&nbsp;</strong>Patients with IPMN had a better prognosis than PDAC patients, regardless of disease stage.</p>

restrictedJan 2022View details →
zenodo16/100

Dataset related to article "Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy "

<p>This record contains raw data related to article &ldquo;Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy&quot;</p> <p>Abstract:</p> <p><strong>Background: </strong> to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT).</p> <p><strong>Material and methods: </strong> Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score.</p> <p><strong>Results: </strong> 997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group.</p> <p><strong>Conclusion: </strong> moving from easily accessible clinical parameters, a score was created to help the physician&#39;s decision about the better treatment or combination of treatments for the individual patient.</p>

restrictedOct 2022View details →
zenodo16/100

Dataset related to article "Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up"

<p>This record contains raw data related to article &quot;Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up&quot;</p> <p>BACKGROUND:</p> <p>The aim of this study was to evaluate long-term efficacy and survival prognostic factors of stereotactic body radiation therapy (SBRT) for un-resectable liver metastases in patients enrolled in a prospective phase II trial.</p> <p>METHODS AND MATERIALS:</p> <p>5-year local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with un-resectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75Gy in 3 consecutive fractions.</p> <p>RESULTS:</p> <p>A total of 61 patients with 76 lesions were enrolled, with a median follow-up time of 6.1&thinsp;years. One, three and 5 year LC rates were 94&thinsp;&plusmn;&thinsp;3.1%, 78.0&thinsp;&plusmn;&thinsp;5.9% and 78.0&thinsp;&plusmn;&thinsp;5.9%, without reaching the median LC time. Median OS was 27.6&thinsp;months and the survival rates were 85.2&thinsp;&plusmn;&thinsp;4.5%, 31.1&thinsp;&plusmn;&thinsp;5.9% and 18.0&thinsp;&plusmn;&thinsp;4.9% at 1, 3 and 5-year after SBRT, respectively. Univariate analysis showed that favorable primary site (colorectal, breast and gynecological) of metastases (p&nbsp;=&thinsp;0.001) improved survival. Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1&thinsp;year from SBRT. No cases of Radiation Induced Liver Disease (RILD) were detected.</p> <p>CONCLUSIONS:</p> <p>Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.</p>

restrictedSep 2019View details →
zenodo16/100

Dataset related to article "Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy"

<p>This record contains raw data related to article<br> &quot;Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy&quot;</p> <p>Colorectal cancer (CRC) represents one of the major leading causes of death from cancer. Aim of the present study was to analyze outcome of oligometastatic CRC patients treated with stereotactic body radiation therapy (SBRT), and to evaluate predictive factors of survival.</p> <p>MATERIALS AND METHODS:</p> <p>We included patients with maximum 5 metastases. Previous/concomitant systemic treatments were allowed. End points of the present study were the outcome in terms of Local control of treated metastases (LC), progression free survival (PFS), and overall survival (OS).</p> <p>RESULTS:</p> <p>437 metastases were treated in 270 patients. Lung was site of metastases in 48.5% of cases, followed by liver (36.4%). Systemic treatment was administered before SBRT in 199 patients (73.7%). Median follow-up time was 23 months (3-98.7). Rates of LC at 1, 3 and 5 years were 95%, 73% and 73%, respectively. Time from diagnosis of metastases to SBRT was the only factor predictive of LC (HR 1.62, p = 0.023). Median PFS was 8.6 months. Rates of OS at 1, 3 and 5 years were 88.5%, 56.6%, and 37.2%, respectively. Lesion greater than 30 mm (HR 1.82, p = 0.030), presence of non-lung metastases (HR 1.67, p = 0.020), the use of systemic treatment before SBRT (HR 1.82, p = 0.023), and progression of treated metastases (HR 1.80, p = 0.007), were all predictive of worse OS.</p> <p>CONCLUSIONS:</p> <p>Stereotactic body radiation therapy represents an effective approach in the management of oligometastatic CRC. Control of treated oligometastases seems to be a strong positive predictive factor for both PFS and OS.</p>

restrictedSep 2019View details →
zenodo16/100

Clinical Dataset for Risk Factors for Overall Survival in Hospitalized Adults Receiving Total Parenteral Nutrition: A Retrospective Cohort Study at a Social Security Hospital in Peru: January 2022 – June 2023

<p>This Excel dataset contains de-identified clinical data collected over a two-year period, aimed at evaluating risk factors associated with 90-day mortality in hospitalized patients receiving total parenteral nutrition (TPN). The dataset includes variables such as age, sex, clinical diagnosis, comorbidities, days in the ICU, days receiving TPN, laboratory values (lymphocytes, platelets, TGP), and the presence of acute kidney injury (AKI) or chronic kidney disease (CKD).</p> <p>The data is structured in rows, with each row representing an individual patient, and columns corresponding to the various clinical and laboratory parameters. It was used to perform survival analysis using Cox proportional hazards models and other statistical techniques. Sensitive information has been removed to ensure patient confidentiality.</p> <p>Access to the dataset is restricted, and permission must be requested for its use in further research.</p> <p><strong>File format:</strong> Excel (.xlsx)<br><strong>Keywords:</strong> Total Parenteral Nutrition, 90-Day Mortality, Risk Factors, Clinical Dataset, Cox Regression</p>

restrictedcc-by-4.0Sep 2024View details →
zenodo16/100

Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS)

<p>Raw annonymized data, OncoScan CEL files of the manuscript.</p> <p>PMID: 27775850</p> <p>DOI: 10.1111/his.13106</p> <p>ABSTRACT:</p> <p><strong>Aims: </strong> We aimed to define the clinicopathological characteristics of 29 primary sinonasal diffuse large B cell lymphoma (DLBCL<sup>sn</sup> ) in a series of 240 cases of DLBCL not otherwise specified [DLBCL<sup>all (</sup><sup>NOS</sup><sup>)</sup> ], including DLBCL<sup>sn</sup> training set (n = 11) and validation set (n = 18), and DLBCL<sup>non-sn</sup> (n = 211).</p> <p><strong>Methods and results: </strong> In the training set, 82% had a non-germinal center B-cell-like (Hans&#39; Classifier) (non-GCB) phenotype and 18% were Epstein-Barr virus-encoded small RNAs (EBER)<sup>+</sup> . The genomic profile showed gains<sup>(+)</sup> of 1q21.3q31.2 (55%), 10q24.1 (46%), 11q14.1 (46%) and 18q12.1q23 (46%); losses<sup>(-)</sup> of 6q26q27 (55%) and 9p21.3 (64%); and copy number neutral loss of heterozygosity (LOH) (acquired uniparental disomy, UPD) at 6p25.3p21.31 (36%). This profile is comparable to DLBCL<sup>NOS</sup> (GSE11318, n = 203.) and closer to non-GCB/activated B-cell-like subtype (ABC). Nevertheless, +1q31, -9p21.3 and -10q11.1q26.2 were more characteristic of DLBCL<sup>sn</sup> (P &lt; 0.001). Array results were verified successfully by fluorescence in situ hybridization (FISH) on +1q21.3 (CKS1B), -6q26 (PARK2), +8q24.21 (MYC), -9p21.3 (MTAP, CDKN2A/B), -17p13.1 (TP53) and +18q21.33 (BCL2) with 82-91% agreement. Minimal common regions included biologically relevant genes of MNDA (+1q23.1), RGS1 and RGS13 (+1q31.2), FOXP1 (+3p13), PRDM1 (BLIMP1) and PARK2 (-6q21q26), MYC (+8q24.21), CDKN2A (-9p21.3), PTEN (-10q23.31), MDM2 (+12q15), TP53 (-17p13.1) and BCL2 (+18q21.33). Correlation between DNA copy number and protein immunohistochemistry was confirmed for RGS1, RGS13, FOXP1, PARK2 and BCL2. The microenvironment had high infiltration of M2-like tumour associated macrophages (TAMs) and CD8<sup>+</sup> T lymphocytes that associated with higher genomic instability. The DLBCL<sup>sn</sup> validation set confirmed the clinicopathological characteristics, all FISH loci and immunohistochemistry (IHC) for RGS1. RGS1, one of the most frequently altered genes, was analysed by IHC in DLBCL<sup>all</sup> and high RGS1 expression associated with non-GCB, EBER<sup>+</sup> and unfavourable overall survival (hazard ratio = 1.794; P = 0.016).</p> <p><strong>Conclusions: </strong> DLBCL<sup>sn</sup> has a characteristic genomic profile. High RGS1 IHC expression associates with poor overall survival in DLBCL<sup>all (</sup><sup>NOS</sup><sup>)</sup> .</p>

restrictedDec 2022View details →
zenodo16/100

Dataset related to article "Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer"

<p>This record contains raw data related to article &ldquo;Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer&quot;</p> <p>Abstract</p> <p>In recent years, immunohistochemical protein expression was studied as a surrogate to the molecular classification of bladder cancer, although no tissue biomarkers are available for clinical use to predict survival or the response to neoadjuvant chemotherapy (CT) in UC, as the literature produced conflicting results. This retrospective study included TURB specimens harboring foci of HG pT2 muscle-invasive bladder carcinoma (MIBC) from 251 patients who subsequently underwent radical cystectomy. We performed immunohistochemical analysis on tumor samples, for relevant gene-expression-based markers for basal type (<em>CD44</em>, <em>CK5/6</em>) and luminal type (<em>CK20</em> and <em>pPAR&gamma;</em>). Piescore, investigated in both non-muscle-invasive (NMI) and muscle-invasive (MI) components of the tumor, divided basal and luminal UC-types when at least three of the four markers were consistent with a specific phenotype, mixed types if one/two luminal and basal markers were present simultaneously, and neu-like types when all four markers investigated were negative. Eighteen selected cases were also investigated with RT-PCR to validate, and to increase the specificity of, the immunohistochemical results. We observe an immunophenotypical difference in the NMI and MI components in 96/251 UC patients (38.25%): half of tumors (44/96 cases) have a transition to basal, 36.46% (35/96 cases) to neu-like, 12.5% (12/96 cases) to mixed, and 5.2% (5/96 cases) to luminal phenotypes. Mixed tumors in the NMI component are more likely to change phenotype than other groups, particularly compared with basal tumors, which demonstrate greater stability (only 8/96 cases, <em>p</em> &amp;lt; 0.00001). The transition of luminal tumors to basal display a better OS compared with the transition toward neu-like tumors (<em>p</em> = 0.027). Overall, the phenotypical switch does not affect lymphovascular invasion, pT, DFS, or OS compared with non-switched cases. In the MI component, the presence of <em>CD44</em> expression, irrespective of score-related phenotype, shows a protective effect in papillary-type UC (OS <em>p</em> = 0.008, HR 0.453, PFS <em>p</em> = 0.07, HR 0.599), and in UC na&iuml;ve for CT (<em>p</em> = 0.0479). Piescore immunophenotyping reveals an intratumoral phenotypical transition between the NMI and MI components of the same tumor. The molecular change is a common event in the mixed and luminal categories, but not in basal tumors, which show better phenotypical stability. This phenomenon could partially explain the sensitivity of a subset of luminal UC to chemotherapy: good responders could be &quot;non-real&quot; luminal UC, which acquire nasal markers, such as <em>CD44</em>.</p>

restrictedJan 2023View details →
zenodo16/100

Dataset related to article "PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival "

<p>This record contains raw data related to article &quot;PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival&quot;</p> <p>Abstract</p> <p><strong>Purpose: </strong> Intrahepatic cholangiocarcinoma (IHC) is an aggressive disease with few reliable preoperative biomarkers. This study aims to elucidate if radiomics extracted from preoperative [18F]FDG PET/CT may grant a non-invasive biological characterization of IHC and predict outcome after complete resection of the tumor.</p> <p><strong>Methods: </strong> All patients preoperatively imaged by [18F]FDG PET/CT who underwent hepatectomy for mass-forming IHC in the period 2010-2019 were retrospectively evaluated. On PET images, manual slice-by-slice segmentation of IHC was performed (Tumor-VOI). A 5-mm margin region was semi-automatically generated around the tumor (Margin-VOI). Textural analysis was performed using the LifeX software. Analyzed outcomes included tumor grading (G3 vs. G1-2), microvascular invasion (MVI), overall survival (OS), and progression-free survival (PFS). The performances of the combined clinical-radiomic models were compared with those of standard clinical models.</p> <p><strong>Results: </strong> Overall, 74 patients (40 females, median age 68 years) were included. Considering tumor grading and MVI, the models combining the clinical data and radiomics of the Tumor-VOI had better performances than the clinical ones (AUC = 0.78 vs. 0.72 for grading; 0.87 vs. 0.78 for MVI). The inclusion into the models of radiomics of the Margin-VOI further improved the prediction of grading (AUC = 0.83), but not of MVI. Considering OS and PFS, the models including the preoperative clinical data and radiomics of the Tumor-VOI and Margin-VOI had better performances than the pure clinical ones (C-index = 0.81 vs. 0.76 for OS; 0.81 vs. 0.72 for PFS) and similar to the models including the pathology and postoperative data (C-index = 0.81 for OS; 0.79 for PFS). No model retained the standard SUV measures.</p> <p><strong>Conclusion: </strong> The PET-based radiomics of IHC can predict pathology data and allow a reliable preoperative evaluation of prognosis. The radiomics of both the tumoral and peritumoral areas had clinical relevance. The combined clinical-radiomic models outperformed the pure preoperative clinical ones and achieved performances non-inferior to the postoperative models.</p>

restrictedJan 2023View details →
zenodo16/100

Survival of the Senior Civil Servants in the Chilean Executive Branch

<p><strong>Survival of the Senior Civil Servants in the Chilean Executive Branch</strong></p> <p>This repository contains a novel data set of senior public managers in Chile during the 2009-2017 period.&nbsp;This is a pre-release version of the dataset under restricted access.</p>

restrictedNov 2021View details →
zenodo16/100

Spatial Organization of MFAP5+ Fibroblasts within Gastric Cancer Tumor Microenvironment Predicts Better Survival

<p>This dataset contains the IMC data and code associated with&nbsp;<em>Spatial Organization of MFAP5+ Fibroblasts within Gastric Cancer Tumor Microenvironment Predicts Better Survival</em></p> <p>this dataset contains:</p> <ul> <li>Processed spatial single-cell data</li> <li>Code for analysis</li> </ul>

restrictedcc-by-4.0Aug 2024View details →
ClinicalTrials.gov16/100

Validity of Different Prognostic Models Assessing 1 Year Survival After Liver Transplantation

ClinicalTrials.gov study NCT02412280. IPD Sharing: Not stated. Countries: 0. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo16/100

Chromatin structure predicts survival in glioma patients

GEO Series GSE295378. Homo sapiens. 38 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.

openGEO-OpenApr 2025View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.